Agrawal Surendra S, Baliga Vrinda, Londhe Vaishali Y
Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DU), Sawangi (M), Wardha 442001, Maharashtra, India.
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai 400056, Maharashtra, India.
Pharmaceutics. 2024 Dec 30;17(1):36. doi: 10.3390/pharmaceutics17010036.
Liposome-based drug delivery technologies have showed potential in enhancing medication safety and efficacy. Innovative drug loading and release mechanisms highlighted in this review of next-generation liposomal formulations. Due to poor drug release kinetics and loading capacity, conventional liposomes have limited clinical use. Scientists have developed new liposomal carrier medication release control and encapsulation methods to address these limits. Drug encapsulation can be optimized by creating lipid compositions that match a drug's charge and hydrophobicity. By selecting lipids and adding co-solvents or surfactants, scientists have increased drug loading in liposomal formulations while maintaining stability. Nanotechnology has also created multifunctional liposomes with triggered release and personalized drug delivery. Surface modification methods like PEGylation and ligand conjugation can direct liposomes to disease regions, improving therapeutic efficacy and reducing off-target effects. In addition to drug loading, researchers have focused on spatiotemporal modulation of liposomal carrier medication release. Stimuli-responsive liposomes release drugs in response to bodily signals. Liposomes can be pH- or temperature-sensitive. To improve therapeutic efficacy and reduce systemic toxicity, researchers added stimuli-responsive components to liposomal membranes to precisely control drug release kinetics. Advanced drug delivery technologies like magnetic targeting and ultrasound. Pro Drug, RNA Liposomes approach may improve liposomal medication administration. Magnetic targeting helps liposomes aggregate at illness sites and improves drug delivery, whereas ultrasound-mediated drug release facilitates on-demand release of encapsulated medicines. This review also covers recent preclinical and clinical research showing the therapeutic promise of next-generation liposomal formulations for cancer, infectious diseases, neurological disorders and inflammatory disorders. The transfer of these innovative liposomal formulations from lab to clinical practice involves key difficulties such scalability, manufacturing difficulty, and regulatory limits.
基于脂质体的药物递送技术在提高用药安全性和疗效方面已显示出潜力。本综述重点介绍了下一代脂质体制剂中创新的药物装载和释放机制。由于药物释放动力学和装载能力较差，传统脂质体的临床应用有限。科学家们已开发出新的脂质体载体药物释放控制和包封方法来解决这些限制。通过创建与药物电荷和疏水性相匹配的脂质组合物，可以优化药物包封。通过选择脂质并添加共溶剂或表面活性剂，科学家们在保持稳定性的同时增加了脂质体制剂中的药物装载量。纳米技术还创造了具有触发释放和个性化药物递送功能的多功能脂质体。聚乙二醇化和配体偶联等表面修饰方法可以将脂质体导向疾病区域，提高治疗效果并减少脱靶效应。除了药物装载，研究人员还专注于脂质体载体药物释放的时空调节。刺激响应型脂质体可根据身体信号释放药物。脂质体可以对pH值或温度敏感。为了提高治疗效果并降低全身毒性，研究人员在脂质体膜中添加了刺激响应成分，以精确控制药物释放动力学。先进的药物递送技术如磁靶向和超声。前药、RNA脂质体方法可能会改善脂质体药物给药。磁靶向有助于脂质体在患病部位聚集并改善药物递送，而超声介导的药物释放则有助于按需释放包封的药物。本综述还涵盖了最近的临床前和临床研究，这些研究显示了下一代脂质体制剂在癌症、传染病、神经疾病和炎症性疾病治疗方面的前景。将这些创新的脂质体制剂从实验室转移到临床实践涉及关键难题，如可扩展性、制造难度和监管限制。
